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Abstract 
Purpose – To review evidence from high quality randomised controlled trials reporting 
links between omega-3 enriched functional foods and health. 
Design/methodology/approach – Using Medline, a search was made for all randomised 
controlled trials published between 2002 and 2012 that met defined inclusion criteria. 
Studies had minimum durations of 28-days, clearly stated the food vehicle, dose and type 
of long chain omega-3 polyunsaturated fatty acids (LC3PUFA) used and did not include 
studies where participants only took LC3PUFA supplements. 
Findings - A total of eleven studies were located, ten of which reported potential health 
benefits linked to omega-3 functional food consumption.  Five studies reported significant 
improvements in markers of cardiovascular (CV) health while ten bioavailability studies 
reported increases in omega-3 blood levels when doses of 460mg or more were integrated 
into food vehicles.  
Research limitations/implication – In the future a meta-analysis would be useful in terms 
of determining the dose of LC3PUFA associated with overall health benefits.  
Practical implications - The present review concludes that omega-3 enriched functional 
foods are a useful way to improve LC3PUFA status and have been linked to improved 
health outcomes, namely markers of CV health.  More work is now needed to determine 
whether particular population groups could benefit from consumption of these foods e.g. 
vegetarians and children in relation to a range of health outcomes, such as cognitive 
function. 
Originality/value – This review provides evidence that integrating omega-3 enriched 
functional foods within the daily diet could be an effective strategy for helping to improve 
LC3PUFA status and attenuating CV disease risk. 
 
Key words - Omega 3, enriched/functional foods, cardiovascular disease. 
 
Article Classification - General review 
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Introduction 
Functional foods are whole, fortified, enriched or enhanced foods that provide additional 
health benefits (Buttriss 2010).  There is increasing evidence that certain population 
groups may not be consuming enough long chain omega-3 (n-3) polyunsaturated fatty 
acids (LC3PUFA).  There are many reasons for this.  Currently, the richest dietary source 
of LC3PUFA is marine originated (Degirolamo et al., 2010), making it inappropriate for 
vegetarians, including ethnic groups who do not consume fish.  Equally, many people do 
not like the taste and/or texture of fish and signs of gastrointestinal upset, fishy aftertaste 
and repetition have been linked to the use of fish oil supplements (Fetterman and 
Zdanowicz 2009).   
 
Even in population groups that are fish-eaters this is under consumed.  The National Diet 
and Nutrition Survey (NDNS) found only around 8g oily fish is being consumed by UK 
adults on a daily basis.  Oily fish consists of only a third of fish intakes rather than the 
recommended 50 per cent (Ruxton 2011).  Consumer preferences are generally slanted 
towards lower LC3PUFA content fish including coated or fried white fish and shell fish 
products (Bates et al., 2010).  Equally, data from the UK Low Income Diet and Nutrition 
Survey (LINDS) (Nelson et al., 2007) demonstrate that LC3PUFA consumption is even 
lower in under-privileged households with adults consuming mean intakes of 6g/day and 
children 1g/day oily fish.  On the whole it can be seen that UK habitual intakes are 
significantly lower than LC3PUFA dietary guidelines (see Tables 1 and 2).   
(Tables 1 and 2 here). 
 
It is also important to consider the ratio of omega-6 (n-6) to n-3 that is consumed in the 
human diet (Simopoulos 2011).  Essential fatty acids (EFA) alpha-linolenic acid (18:3; n-3 
ALA) and linoleic acid (18:2; n-6 LA) are crucial for healthy cell development, nervous 
system and brain function; they must be obtained through the diet as they cannot be 
manufactured in the body (Koletzko et al., 2008).  The metabolic pathways for EFA’s 
interlink; EFA’s undergo a series of desaturation and elongation reactions to synthesize 
long chain polyunsaturated fatty acids.  ALA is the n-3 parent fatty acid which is converted 
to eicosapentaenoic (20:5; n-3 EPA) and docosahexaenoic (22:6 n-3 DHA) acids (naturally 
found in oily fish) through the n-3 metabolic pathway (DeFilippis and Sperling 2006).   
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The n-6 and n-3 fatty acids compete for the enzymes that convert them.  Conversion of n-6 
is usually highly effective and excessive dietary consumption of LA can significantly 
decrease the conversion of ALA.  Evidence from dietary surveys suggests this is the case 
in the UK and parts of Western Europe (Linseisen et al., 2009 ; Bates et al., 2010 ; 
Simopoulos 2011).  To accommodate this the recommendations of the International 
Society for the Study of Fatty Acids and Lipids (2004) suggest the dietary ratio of n-6 to n-
3 should be 4 to 1 instead of the current 10 to 1.  The balance of n-6 and n-3 fatty acids is 
important in health to maintain homeostasis and normal development throughout the life 
cycle.  Further integration of n-3 rich foods into the daily diet could enhance this balance 
and may help to improve the publics long-term health (Simopoulos 2011).    
 
For example, studies have shown consistently good evidence linking LC3PUFA 
consumption to a host of health benefits, including improved cardiovascular (CV) health, 
kidney health, mental health, reduction of triglyceride levels and certain cancer forms 
(Geelen et al., 2007 ; Hartweg et al., 2007 ; Miller et al., 2009 ; Carayol et al., 2010 ; Musa-
Veloso et al., 2011).  Current n-3 clinical treatment areas include CV disease, cancer, type 
2 diabetes, depression and stress, inflammatory diseases and Alzheimer’s disease (Gogus 
and Smith 2010).  In relation to health benefits Ruxton et al. (2007) found evidence that an 
increased intake of LC3PUFA could impact positively on the health of many people and 
recommended more work to ensure that those who do not wish to eat oily rich ﬁsh can 
beneﬁt from enhanced intakes of LC3PUFA.  Once more, in relation to fish consumption 
data from the LINDS and NDNS (2007 ; 2010) indicate that only around 13 per cent of the 
general population and 5 and 9 per cent of lower income males and females respectively 
consume a fish oil supplement (Nelson et al., 2007 ; Bates et al., 2010).  In addition, 
further analysis of supplement compliance shows that physically active, non-smoking 
women are most likely to take fish oil supplements and also consume the highest amounts 
of oily fish (Harrison et al., 2004a).  Equally, research by the same scientists found that 
individuals with a history, or markers of CV disease were also less likely to take fish oil 
supplements and concluded that population groups who were least likely to comply with 
supplementation strategies  were generally the ones who needed it most (Harrison et al., 
2004a).   
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On the whole, data from UK dietary surveys indicate that fish intakes for adults are 
consistently low and compliance with supplementation programmes is poor (especially for 
individuals who would benefit from this most).  UK adults are consequently not ingesting 
levels of LC3PUFA that have been associated with health benefits in supplement trials 
(Bates et al., 2010 ; DeFilippis et al., 2010 ; Musa-Veloso et al., 2011).  Additional 
approaches are needed to improve the palatability of LC3PUFA rich foods/supplements 
and delivering this essential nutrient through alternative suitable food vehicles could be 
one way forward.  The aim of this present review paper is to use defined inclusion criteria 
to condense the literature on omega-3 and health to establish whether omega-3 intakes 
from functional food/enriched sources could help to improve: 1) human blood LC3PUFA 
levels and 2) markers of health and wellbeing. 
  
Methods 
Medline was searched for English-language, peer reviewed, randomised controlled trials 
(RCT) published between 2002 and 2012 considering the health benefits of omega-3 
enriched functional foods.  A health benefit was defined as an improvement in clinical risk 
markers associated with a health condition or disease.  Only human studies were included, 
so conclusions could relate to public health. Search terms included “omega-3”, “DHA”, 
“EPA”, “ALA” “enriched/functional foods” and “health”.  In addition to these search terms, 
reference lists of relevant papers were searched to ensure all available studies were 
included.   
Only randomised controlled studies were included.  These were graded using the Scottish 
Intercollegiate Guidelines Network (SIGN) (Scottish Intercollegiate Guidelines Network 
(SIGN) 2008) criteria and the PRISMA checklist (Moher et al., 2009).  In addition, further 
inclusion criteria were that studies should: 
1) Clearly state that no other supplement e.g. fish oil is taken. 
2) Clearly state the sample size for the LC3PUFA intervention. 
3) Clearly state the type and dose of LC3PUFA administered to subjects. 
4) Not be using LC3PUFA from genetically modified plant sources. 
5) Use adults subjects free of serious illness, aged 18 to 75 years. 
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A study was excluded from the review if: 
1) It was an animal or in vitro study. 
2) It was an uncontrolled human intervention study or a retrospective observational 
study. 
3) It was not primary research (for example, opinion letter, position statement, 
systematic review, meta-analysis). 
4) It was published in a language other than English or published in abstract form only 
 
Results 
(Table 3) 
The literature search identified 78 articles, eleven of which used RCT’s that tested the 
potential benefits of LC3PUFA enriched functional foods with adult populations (Table 3).  
Five of the studies used healthy volunteers and the remaining six had subjects with 
elevated CV disease risk factors including high blood pressure, hypercholesterolemia and 
atherosclerosis.  Of the eleven adult studies, eight RCT’s used fish oil as the source of 
LC3PUFA.  Four studies recruited RCT’s to test fish-based LC3PUFA source oils using 
enriched drinking products.   
 
In a medium-term intervention study Fujioka et al. (2006) used 2.2g/day fish oil providing 
0.60g/d EPA and 0.26g/d DHA to enrich a soymilk drink, which was consumed by 141 
healthy, mostly middle-aged volunteers.  Subject compliance was good during the twelve 
week trial and although the study lost a total of sixteen volunteers, only four withdrew 
because of side-effects associated with the fortified soymilk product.  Authors noted a 
significant increase in EPA red blood cell concentrations after 12 weeks (P<0.001).  
Similar results were also recorded by Köhler et al. (2010) who developed a salmon oil 
fortified convenience drink, which was given to 50 patients in a short term single-centre 
study.  The dose and preparation methods used to formulate the product were found to be 
safe, and the product was well tolerated and described as highly palatable by the study 
participants.  The provision of 200mg EPA and 300mg DHA per day was found to 
significantly increase the n-3 index of 50 patients with atherosclerotic disease (P<0.001).     
Castro et al. (2007) developed a fish oil fortified milk formulation which was given to 99 
healthy adult volunteers for six weeks providing a daily dose of 460mg/d LC3PUFA.   
7 
 
The participants were clustered and allocated to treatment sub-groups in accordance with 
their individual coronary heart disease (CHD) risk level.  Blood cholesterol markers, body 
mass index, age, and waist circumference measures were used to determine CHD risk 
levels.  Significant increases were noted in blood plasma EPA and DHA during the study 
period (P=0.001) for all supplemented groups, although there were no changes in 
triacylglycerol levels.  The addition of soluble dietary fibres was found to increase the 
sensory quality of the milk formulation.  However, the intervention group suffered high 
participant dropout levels (n=29) mainly because the subjects were able to detect a fishy 
taste in the fortified milk.   
 
A parallel RCT by Kirkhus et al. (2012) used fish oil to enriched a fruit drink and fish pâté 
which were given to healthy participants.  Significant increases were noted compared to 
baseline in EPA and DHA levels for both dietary sources along with the supplement.  
Participants consuming the fruit drink also had increased ALA levels (P=0.05), although 
EPA and DHA rises were lower than those randomised to the pâté or supplement groups.  
Authors concluded that enriched pâté and fruit juice were safe, well tolerated and highly 
palatable alternatives to supplementation.  They also concluded that the fruit juice product 
could also be advised for individuals who do not like fish or fish oil capsules.  However, 
unfortunately neither of the products in this trial would be suitable for vegetarians or non-
fish eaters.    
 
The remaining seven studies used LC3PUFA source oils to create enriched functional food 
products.  Mukaro et al. (2008) offered a variety of different cod liver oil fortified foods 
including baked and dairy products, chocolate, dips, milk, muesli, salad dressings and 
soup.  Healthy participants were able to choose eight foods per day, with the objective of 
receiving a LC3PUFA dose of 1000mg/d and 44 volunteers took part in the six month 
intervention.  The study was designed to assess whether LC3PUFA supplementation gave 
protection against inflammation and resulted in significantly decreased inflammatory 
reactions in the form of lower numbers of natural killer cells, reduced neutrophil iodination 
activity and decreased tissue damage in participants (P<0.05).  Total LC3PUFA 
erythrocyte membrane and phospholipid levels were also significantly improved in the 
intervention group (P<0.001) indicating increased LC3PUFA bioavailability.  Overall, the 
study found that LC3PUFA enriched foods reduced markers of inflammation and tissue 
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damage, which has only been reported previously using supplementation trials (Thies et 
al., 2001). 
 
Trials by Harrison et al. (2004b), Dawczynski et al. (2010) and Murphy et al.(2007) 
investigated a variety of fish-oil enriched food products including baked goods, dairy 
products, cereals and sauces using middle aged and older participants with elevated CV 
disease risk factors.  The three trials shared a similar aim, which included the development 
of enriched functional foods that could be used to reduce key CHD or CV disease risk 
factors.  Researchers noted a significant increase in high density lipid cholesterol (HDL-C) 
levels (95% CI 2.5%, 9.6%) in the participants of the intervention by Harrison et al.(2004b).  
All of the trials demonstrated how functional foods can be used to significantly increase 
blood levels and bioavailability of LC3PUFA (P≤0.05).  In addition, for the trial by 
Dawczynski et al.(2010); where participants with elevated triacylglycerol levels consumed 
fortified dairy products such as cheese and yogurt, significant improvements in CV risk 
factors (total cholesterol, triacylglycerol, and HDL-C:LDL-C ratios) were reported (P≤0.05).  
This would suggest that LC3PUFA enriched functional foods could be utilised to improve 
CHD and CV risk factors.  
  
A long-term trial was designed by Patch et al.(2005).  The aim was to increase LC3PUFA 
consumption in overweight adults with mildly elevated triglyceride levels and low fish 
consumption.  Applicants were given a wide choice of functional foods including baked 
goods, dairy products, sauces, cereal and soup.  The dose was set at 1g/d EPA and DHA 
for six months although the LC3PUFA source was not stated.  At the end of the trial period 
the intervention group members significantly increased their intake of LC3PUFA in 
comparison to baseline values (P<0.001).  As the trial was designed purely to increase 
consumption, further health markers such as plasma or erythrocyte LC3PUFA and 
triglyceride levels were not measured.  Therefore the trials did not establish whether an 
increase of dietary LC3PUFA offered any health benefits to the study participants.    
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A further trial by Bloedon et al.(2008) used a vegetarian LC3PUFA source with the aim of 
modulating CV disease risk.  An ALA fortified food product was given to adult participants 
with raised cholesterol levels for ten weeks.  The study, which used 40 grams of ground 
flaxseed providing a dose of 3.8g/d ALA to fortify honey bread noted adverse effects 
including diarrhoea, flatulence, and headaches in both the intervention and control groups.  
In addition to the benefits of plant based n-3 (ALA) the authors hypothesized that the 
dietary fibre and lignans contained in whole flaxseed might exhibit lipid lowering properties.  
The intervention participants demonstrated a significant increase in ALA plasma levels 
(P<0.001) and a modest but short lived low density lipid cholesterol (LDL-C) lowering 
effect (P<0.05).   However, no significant differences were noted in EPA and DHA blood 
levels which would suggest some doubt as to whether ALA vegetarian sources should be 
used as a fish oil replacement for vegetarians.      
 
Only one study has investigated vegetarian alternatives to ALA, using sea algae (Arterburn 
et al. (2007).  Algae are the primary source of DHA in the marine food chain and its 
potential health benefits are largely understudied (Brunner et al., 2009).  The main aim of 
the trial was to assess the bioequivalence of two algal DHA sources that are currently 
used for fortification of infant formula and in dietary supplementation of adults including 
pregnant women.  The trial mainly examined supplementation, however 465mg of DHA 
rich algae oil was also used to fortify a chocolate coated, coconut snack bar, which was 
given to 12 healthy participants (one bar per day) for 28 days as part of the larger 
supplementation trial.  The study results indicated that both algal oil sources were 
bioequivalent sources of DHA.  The snack bars were found to give equivalent 
bioavailability to supplements in the study and were well tolerated by the intervention 
group.  In terms of dosage, the snack bar offered a comparative plasma and erythrocyte 
DHA increase to the 600mg/d supplement.  This suggests that LC3PUFA bioavailability 
(from algae sources) may be improved when oils are incorporated into functional foods.   
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Discussion  
A comparison of recommended LC3PUFA intakes and current habitual intakes identifies 
that consumption falls below the necessary amounts (Tables 1 and 2).  The population 
groups most in need of a direct LC3PUFA source appear to consume the lowest amounts 
of fish in their diet.  It seems that the majority of Western populations do not choose to eat 
sufficient quantities of oily fish.  This position may further deteriorate in light of current 
concerns about fish contamination and sustainability (Aberg et al., 2009).  Consumption of 
fish may be at low levels for a number of reasons.  Fish markets and fishmongers in the 
high street have declined and only certain supermarkets offer a wet fish counter making 
fresh fish less readily available (Leek et al., 2000).  Research by Verbeke et al. (2005) 
suggests that fish consumption is higher in women and increases with age, indicating that 
the diets of younger people and males may be lacking in LC3PUFA. 
 
The lowest income classes have the lowest fish consumption and the presence of children 
in the household leads to further reduced fish consumption.  Oily fish eaters currently 
account for only around 27 per cent of the population (Givens et al., 2006).  Barriers to fish 
consumption may include concerns about bones and a lack of confidence in the choice of 
good quality fish from supermarkets and preparation methods for cooking (Ruxton 2011).  
Cost may also be an issue, particularly in low income households.  Growing awareness of 
the health benefits associated with oily fish coupled with official guidelines to increase fish 
consumption have intensified demand, this in turn has impacted on low income 
households as fish prices have increased in most developed countries (Trondsen et al., 
2003).  Supplies of wild fish from the ocean are a limited commodity.  As evidence of the 
health benefits mounts it is likely that demand for oily fish and fish oil products will continue 
to increase.  In 2007 around 28 per cent of world fish stocks were overexploited, depleted 
or recovering from depletion (Fisheries and Aquaculture Department 2008).  Therefore, 
novel alternatives to marine LC3PUFA sources warrant future research (Brunner et al., 
2009).  Further non vegetarian LC3PUFA sources are available in the form of meat and 
poultry, although the content is somewhat variable and current intakes obtained from these 
sources fall far below recommended amounts.  The LC3PUFA content of meat and poultry 
can vary considerably depending on the source and origin of products coupled with the 
fact that fish products have been excluded from ruminant diets for a number of years 
(Givens et al., 2006).   
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The MEDLINE search identified eleven key studies that met the search criteria and used 
LC3PUFA functional foods to increase intakes in adult population groups.  Ten of the trials 
reported significant increases in blood LC3PUFA levels in participating adults and five 
demonstrated potential health benefits (Harrison et al., 2004b ; Murphy et al., 2007 ; 
Bloedon et al., 2008 ; Mukaro et al., 2008 ; Dawczynski et al., 2010).  Clinical health 
outcomes including measurement of blood cholesterol markers, blood pressure, 
inflammatory markers and tissue damage were measured in seven of the studies.  
LC3PUFA enriched foods offering doses between 1g and 3.8g/d LC3PUFA were found to 
give health benefits in the form of reduced cholesterol levels and decreased inflammatory 
markers and tissue damage in three of the trials (Bloedon et al., 2008 ; Mukaro et al., 2008 
; Dawczynski et al., 2010) although the use of healthy participants in some trials may have 
limited findings in relation to health benefits.  The dosages used in studies with health 
benefits are consistent with findings made in a LC3PUFA supplementation meta-analysis 
by Hartweg et al. (2007), who concluded that LC3PUFA offer cholesterol lowering effects 
and that high doses (>2g/d) may offer greater benefits in this area.   
 
A further trial by Patch et al.(2005) aimed to demonstrate how functional foods can be 
used to improve LC3PUFA intakes, so blood measurements were not taken.  Despite the 
wide range of benefits offered by LC3PUFA in health and illness, so far the majority of 
research involving functional or enriched foods has revolved around the potential benefits 
offered to CV disease and CHD patients.  A selection of everyday staple foods were 
chosen as enrichment vehicles for the trials, examples include baked products like bread, 
cereal and milk (Table 3).  Evidence from the NDNS and LINDS indicates that these foods 
are widely consumed and could be more appealing to lower income families who cannot 
afford to purchase fish on a regular basis (Bates et al., 2010; Nelson et al., 2007). 
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Most of the trials identified used fish oil LC3PUFA source oils to enrich functional food or 
drinks.  If these products were to be used as a method to increase general LC3PUFA 
consumption they would automatically be unsuitable for certain members of the population 
such as vegetarians, vegans, certain ethnic groups and non-fish eaters.  ALA rich sources 
such as flaxseed could be used as an alternative to fish products.  However this would be 
reliant on the desaturation and elongation processes of the n-3 metabolic pathway.  
Previous research has established that conversion of ALA to the longer chain fatty acids 
EPA and DHA is limited (Deckelbaum and Torrejon 2012).  Burdge et al. (2002 ; 2002) 
completed intervention trials with young males and females to measure the capacity for 
conversion of ALA to LC3PUFA.  Males were found to have a very low or absent capacity 
to convert ALA to DHA, the authors recommended that uptake of a pre-formed DHA 
source from the diet may be critical in order to maintain adequate membrane 
concentrations in adult males.   
      
It would therefore seem logical that a direct vegetarian source of DHA such as algae oil 
could offer a solution for the previously discussed groups who cannot or do not want to 
consume fish or fish oils.  Oils produced from marine-algae sources are vegetarian, 
kosher, halal and suitable for vegans.  They are contaminant free and could be used to 
provide a direct, vegetarian source of DHA and EPA through retro-conversion (Conquer 
and Holub 1996 ; Conquer and Holub 1997).  Following further research to investigate the 
broader health benefits and appropriate dosages, algae oil enriched functional foods could 
be used as an alternative to oily fish and fish oil supplements, to improve intakes and 
health markers of at risk groups within the population.   
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Overall conclusions 
Presently UK oily fish and omega-3 intakes appear to fall short of recommended 
standards.  Consequently, this could have implications for the populations’ health and 
wellbeing.  Omega-3 enriched foods have great potential in terms of providing health 
benefits observed in supplement trials.  These foods could be used as a vehicle to improve 
omega-3 intakes in populations with low intakes, and may offer a suitable alternative to 
those who dislike oily fish or taking supplements.  These foods also offer potential in terms 
of correcting omega-3 imbalances whilst improving markers of health, with most of the 
evidence showing improvements in markers of CV disease and CHD.  In order to facilitate 
future research and policy recommendations, further work is now needed to investigate the 
broader potential health benefits of these foods, beyond heart health. 
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Table 1.  Recommended LC3PUFA intakes 
Population group Recommended intake Source 
 
Adult men aged 19 to 70yrs 1.6 g/d ALA (Institute of Medicine of the 
National 2002) 
Adult women aged 19 to 70yrs 1.1 g/d ALA (Institute of Medicine of the 
National 2002) 
Healthy adults 0.7 per cent of energy 
or 0.5g/d LC3PUFA  
(International Society for the Study 
of Fatty Acids and Lipids 2004) 
Healthy adults  0.45g/d LC3PUFA 
(from oily fish) 
(Scientific Advisory Committee on 
Nutrition 2004) 
Healthy adults (to maintain 
healthy LC3PUFA 
concentrations 
350-400mg/d EPA/DHA 
900mg/d ALA 
(Bjerve et al., 1989) 
CHD patients 1g/d EPA/DHA 
 
(Kris-Etherton et al., 2002) 
General population to promote 
cardiovascular health 
250mg/d LC3PUFA (Musa-Veloso et al., 2011) 
Pregnant mothers 
 
0.2g/d DHA (Koletzko et al., 2008) 
Lactating mothers 
 
0.2g/d DHA (Koletzko et al., 2008) 
Non breast fed infants 0.2 to 0.5g/d (Koletzko et al., 2008) 
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Table 2 Habitual LC3PUFA intakes 
Source Population group/age Sample size Intake and dietary source 
National diet and nutrition survey 
(Bates et al., 2010) 
General population (UK) 
 
1131 8g/d oily fish 
 
Low Income Diet and Nutrition survey 
(Nelson et al., 2007) 
Low income populations (UK) 3728 6g/d oily fish (adults) 
1g/d oily fish (children) 
Low Income Diet and Nutritional 
Survey (Nelson et al., 2007) 
White men (UK) 
Black men (UK) 
Asian men(UK) 
Mixed/other ethnic group men (UK) 
White women (UK) 
Black women (UK) 
Asian women (UK) 
Mixed/other ethnic group women (UK) 
1191 
42 
97 
56 
2038 
70 
141 
70 
1.9g/d n-3 fatty acids 
1.9g/d n-3 fatty acids 
2g/d n-3 fatty acids 
1.8g/d n-3 fatty acids 
1.5g/d n-3 fatty acids 
1.5g/d n-3 fatty acids 
1.8g/d n-3 fatty acids 
1.8g/d n-3 fatty acids 
(Sanders 2009) 
(Conquer and Holub 1997) 
(Sanders 2009) 
Vegetarians  114 
41 
114 
1.1-1.6g/d ALA 
<5mg/d EPA 
0.02g/d DHA 
(Sanders 2009) Vegans 
 
 
59 
59 
59 
1.2-1.8g/d ALA 
0g/d EPA 
0g/d DHA 
(Innis and Elias 2003) Pregnant  55 0.54g/d ALA 
78mg/d EPA 
160mg/d DHA 
(Bates et al., 2010) Children 1.5 to 3 yrs 
4 to 10 yrs  
11 to 18 yrs 
1131 4g/d oily fish 
3g/d oily fish 
2g/d oily fish 
(Lovegrove et al., 2004) British Indian Asian Sikhs 40 1.7 mg/d ALA 
68 mg/d EPA 
112 mg/d DHA 
(Linseisen et al., 2009) European men 36034 2.47 per cent of dietary fat intake 
LC3PUFA 
(Linseisen et al., 2009) European women 36034 2.59 per cent of dietary fat intake 
LC3PUFA 
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Table 3 – Summary of LC3PUFA fortified food studies  
Reference and 
sample size (n) 
Age 
(yrs) 
Source, 
dose/intake 
of n-3 
Food  Methodology LC3PUFA status Health outcomes 
Healthy adults 
(Castro et al., 
2007) n=99 
healthy adults 
 
 
16 - 69  
 
Fish oil 
460mg/d 
 
Fortified milk 
formulation 
 
PC-DB-RCT milk 
given daily for 6 
weeks.  Blood  
cholesterol biomarker 
measured  
 
Significant ↑ in plasma EPA 
and DHA (P≤0.05) noted 
groups receiving fish oil 
supplemented food 
compared with placebo  
 
No significant beneficial 
effects on biomarkers.  This 
may be due to the small 
numbers of treatment 
clusters used in the trial 
(Mukaro et al., 
2008) n=44 
healthy adults 
with ↑ CVD risk 
factors 
23 -63  Cod liver oil 
target of 
1000mg/d 
Selection of 8 
foods including: 
baked, dairy, 
chocolate, dips, 
muesli, cereal, 
sauces, soup 
DB-RCT-PC, subjects 
consumed 1g/d 
EPA/DHA from foods 
that contained 125mg 
per serving for 6 
months 
Erythrocyte EPA and DHA 
levels were significantly ↑ 
than the placebo group 
(P≤0.05) 
LC3PUFA enriched foods 
significantly ↓ natural killer 
cells.  ↓ inflammatory 
reaction and tissue damage 
for the intervention group  
(Fujioka et al., 
2006) n=141 
healthy middle-
aged subjects 
Average 
age late 
thirties 
Fish oil 
2.2g/d 
0.60g/d EPA 
0.26g/d DHA 
Fortified soymilk 
based drinks  
 
PC-DB-RCT.  
Subjects randomly 
allocated to groups 
consumed 125ml of 
soymilk for 12 weeks 
EPA erythrocyte 
concentrations↑  
significantly for  intervention 
group compared to baseline 
and placebo group (P≤0.05) 
↑ Bioavailability, other 
benefits not observed. This 
may be due to the use of 
healthy subjects 
(Arterburn et al., 
2007) n=12 
healthy 
participants ate 
the cereal bar,  
18-70  465mg/d 
Algal DHA oil 
(other groups 
were given 
supplements) 
Algal oil fortified 
snack bars  
PC-RCT-PC 
participants asked to 
consume 1 cereal bar 
per day for 28 days 
Significant ↑ in DHA 
compared to baseline and 
placebo group (P≤0.05).  
Small but insignificant 
increases in EPA  
↑ DHA bioavailability.  
Snack bars delivered 
bioequivalent amounts of 
DHA to that of the  
supplements 
(Kirkhus et al., 
2012) n=159 
healthy M and F 
with normal to 
slightly ↑ CVD 
risk factors 
18-70  1g/d 
EPA/DHA 
from fish oil  
Fish pâté or fruit 
juice 
RCT-PC.  Subjects 
randomised and 
allocated to a food or 
supplement.    
Significant ↑ in plasma 
LC3PUFA ratios.  No 
changes in blood lipids or 
markers of inflammation 
and oxidative stress 
↑ Bioavailability, although 
other benefits not observed. 
This may be due to the use 
of healthy participants 
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Participants 
with medical 
conditions  
(Bloedon et al., 
2008) n=62 M 
and post-
menopausal F 
with 
hypercholesterol
emia   
 
 
 
44 -75  
 
 
 
40g/d ground 
flaxseed 
giving 3.8g/d 
ALA 
 
 
 
Flaxseed 
enriched honey 
bread 
 
 
 
RCT.  Subjects were 
asked to consume 2 
slices of bread for 10 
weeks while following 
a low cholesterol diet 
 
 
 
 
Significant ↑ in ALA plasma 
lipid levels and n-6:n-3 
ratios (P≤0.05) 
 
 
 
Flaxseed significantly ↓ 
LDL-cholesterol after 5 
weeks but not after 10 
weeks 
(Harrison et al., 
2004b) n=213 
adults with 
untreated 
elevated total 
cholesterol or 
blood pressure 
45 - 59  Fish oil.  
2g/d DHA 
Bread, crackers 
and snack bars 
PC-DB-RCT Subjects 
were clustered in 
accordance with 
coronary heart 
disease risk levels.  
Foods consumed for 6 
weeks 
DHA fortified foods 
significantly ↑ plasma DHA 
levels (P≤0.05).   
Adding DHA to staple foods 
might supplement existing 
methods to help reduce CV 
disease mortality and 
morbidity 
 
 
 
(Patch et al., 
2005) n=85 
overweight 
adults with 
mildly elevated 
triacylglycerol 
levels with low 
fish intakes 
20 - 65  Source not 
stated.  1g/d 
EPA/DHA  
Cookies, bread, 
cheese spread, 
chocolate, dips, 
eggs, 
margarine, milk, 
muesli, muffins, 
oat cereal, 
pancakes, salad 
dressing, salsa, 
soup 
RCT, subjects asked 
to consume 1g/d 
EPA/DHA from foods 
that contained 125mg 
per serving for 6 
months  
Not measured This long term study 
demonstrated that 
population intakes of 
LC3PUFA could be 
significantly  ↑ with the use 
of n-3 fatty acid enriched 
processed foods 
(Köhler et al., 
2010) n=50 
patients with 
known 
atherosclerotic 
30 -70  Salmon oil  
EPA 
200mg/d  
DHA 
300mg/d 
Fortified 
convenience 
drink 
PC-RCT-SC, subjects 
consumed the drink 
for 8 weeks with the 
aim of increasing the 
omega 3 index 
The intervention group  
significantly ↑ EPA and 
DHA erythrocyte levels 
compared to baseline 
values and the placebo 
A significant rise in n-3 
index for the intervention 
group 
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disease  (P<0.001) 
(Dawczynski et 
al., 2010) n=51 
M and F with 
mildly elevated 
triacylglycerol 
levels 
Average 
late 50’s 
Fish oil 3g/d 
LC3PUFA 
Enriched dairy 
products such 
as cheese and 
yogurt 
PC-DB-RCT-CO dairy 
products consumed 
for 15 weeks.  10 
week washout then 
groups crossed over 
Significant ↑ in EPA and 
DHA biomarkers (P≤0.001) 
Consumption of enriched 
dairy products gave a 
significant improvement in 
CV risk factors 
(Murphy et al., 
2007) n=86 
overweight 
Australians with 
high 
triacylglycerol 
levels 
20 -65  Target of 
1000mg/d 
DHA from 
cod fish oil 
Choice of 18 
foods including 
baked goods, 
dairy products, 
eggs, dips, 
breakfast 
cereal, 
chocolate, dips, 
salad dressings 
DB-RCT-PC Enriched 
foods contained 125g 
DHA , participants 
asked to consume 8 
foods per day for 6 
months 
EPA and DHA enriched 
foods gave significant ↑ in 
erythrocyte LC3PUFA 
levels after 3 and 6 months 
(P<0.05) 
Erythrocyte LC3PUFA 
levels were ↑ to levels 
consistent with a reduction 
in CV risk 
Key: PC: placebo controlled; DB: double blinded; F: female; M: male; RCT: randomised controlled trial; SC: single centre. 
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